ReproCELL Inc. (4978) said it completed payment on Oct. 20, 2026 for its fourth third-party allotment to CVI Investments, Inc., issuing 2,932,000 new shares at ¥119 each for ¥348.9 million, alongside 29,320 units of its 20th series stock acquisition rights.
ReproCELL Inc. (4978) said its board on Oct. 5 approved the fourth issuance under its equity program with CVI Investments, Inc., selling 2,932,000 new shares at ¥119 each and 29,320 stock acquisition rights exercisable at ¥159 per share, for estimated net proceeds of ¥810.5 million if all rights are exercised.
| Hikari Tsushin, Inc. | |
| Offer price | ¥1,000 per common share |
| M&A / TOB | 1 |
| Guidance | 0 |
| Buybacks | 0 |
| Dividends | 0 |
| Capital | 0 |
| Earnings | 0 |
| People | 0 |
Summaries of public disclosures by Japanese listed companies. Not investment advice; accuracy not guaranteed. Figures and dates in the TDnet originals prevail.
本站內容為日本上市公司公開開示之摘要整理，非投資建議，亦不保證正確。數字與日程以 TDnet 原文為準。
本サイトは日本の上場企業の適時開示を要約したものであり、投資助言ではありません。正確性は保証しません。数値・日程は TDnet の原文が優先します。